Skip to main content
. Author manuscript; available in PMC: 2017 Nov 15.
Published in final edited form as: Cancer Res. 2016 Sep 2;76(22):6669–6679. doi: 10.1158/0008-5472.CAN-16-0571

Figure 5.

Figure 5

Figure 5A, B. Comparison of tumor growth (A) and survival (B) in athymic mice bearing subcutaneous Ramos xenografts treated with either bispecific antibody PRIT or streptavidin-biotin PRIT. Mice were injected with 1.4nmol of 2H7-Fc-C825 (anti-CD20 bispecific), CC49-Fc-C825 (non-binding control bispecific antibody), 1F5-SA (anti-CD20-streptaviding conjugate) or HB8181-SA (non-binding control antibody-streptavidin conjugate), followed 23-hours later by either 5 μg DOTAY-Dextran CA (for bispecific antibodies) or 5.8 nmol NAGB CA (for antibody-streptavidin conjugates). One hour later, 2.4nmol DOTA-Biotin radiolabeled with various amounts of 90Y was injected. Tumor growth results represent the mean tumor volume of Ramos xenografts (±SEM; brown, no treatment; green, 1000μCi 90Y following 1.4 mol CC49-Fc-C825 ; blue, 1000μCi 90Y following 1.4nmol HB8181-SA; red, 1000μCi 90Y following 1.4nmol 1F5-SA; black, 400μCi 90Y following 1.4nmol 2H7-Fc-C825 ; orange square, 700μCi 90Y following 1.4nmol 2H7-Fc-C825 ; magenta, 1000μCi 90Y following 1.4nmol 2H7-Fc-C825).

Figure 5C. Comparison of Tumor Growth of Ramos xenografts in Athymic mice injected with either 1.4 or 2.8nmol 2H7-Fc-C825 (anti-CD20 Bispecific Ab) or CC49-Fc-C825 (Control Bispecific Ab), 1.4nmol 1F5-SA (Anti-CD20-streptavidin conjugate), or 1.4nmol HB8181-SA (control Ab-streptavidin conjugate), followed 23-hours later by either 5μg DOTAY-Dextran (for bispecific antibodies) or 5.8nmol NAGB (for Ab-streptavidin conjugates). One hour later 2.4nmol of 90Y-DOTA-Biotin radiolabeled with 1000μCi was administered. Results represent the mean tumor volume of Ramos xenografts (±SEM; n=10; brown, no treatment; magenta, 1.4nmol CC49-Fc-C825 ; green, 2.8nmol CC49-FC-C825 ; black, 1.4nmol 2H7-Fc-C825 ; orange, 2.8nmol 2H7-Fc-C825 ; blue, 1.4nmol HB8181-SA; red, 1.4nmol 1F5-SA).

Figure 5D. Comparison of survival of athymic mice bearing subcutaneous Ramos xenografts treated with various doses of bispecific antibody PRIT or streptavidin-biotin followed by 1000μCi of 90Y-DOTA-biotin. Mice were treated as described in the legend to figure 5A.